NVI Therapeutics is developing NuFect™, a non-viral platform that delivers DNA into the cell nucleus far more efficiently than conventional DNA delivery — for stronger, longer-lasting, non-integrating gene expression.
Gene therapy today forces a trade-off: viral vectors can change the genome permanently, while mRNA fades within days. NuFect™ takes a different route — actively carrying DNA into the cell nucleus far more efficiently than conventional DNA delivery, so you get the longer-lasting, non-integrating expression that DNA provides, without a virus and without altering the genome.
Paired with lipid nanoparticles, NuFect™ is designed to carry genetic cargo(s) directly to the cells that need it — and, with targeted formulations, to specific tissues and organs throughout the body. It's a platform built to bring efficient, non-viral gene delivery from the lab bench to in vivo medicine.
The possibilities are broad: a single platform behind a new generation of longer-lasting, non-integrating therapies — for autoimmune disease, cancer, and rare genetic conditions — treatments that could work with the body rather than permanently rewriting it. That is the future NuFect™ is built to make possible.
NVI Therapeutics is a biotechnology company founded by researchers in gene delivery, cell engineering, and therapeutic development.
Curious about the science, or interested in partnering or investing? We'd love to hear from you.
info@nvi-therapeutics.comThank you — your message is on its way. We'll be in touch shortly.